Provectus Biopha Financials
Provectus Biopha (PVCT) reported $336K in revenue for fiscal year 2025, down 45.5% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Provectus operates as a capital-funded development company, with minimal revenue and cash burn largely bridged by outside financing.
Over the last three fiscal years, revenue stayed subscale while operating cash outflow remained near$3M ; financing inflows repeatedly replaced that burn, so the business has been functioning as a funded research platform rather than a self-supporting seller. That makes changes in sales less informative than the company’s continued access to external cash.
In FY2025, R&D spending of
The current ratio fell to 0.1x, and year-end cash of
Financial Health Signals
Provectus Biopha does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The metrics below are current.
Key Financial Metrics
Earnings & Revenue
Provectus Biopha generated $336K in revenue in fiscal year 2025. This represents a decrease of 45.5% from the prior year.
Provectus Biopha earned -$0.01 per diluted share (EPS) in fiscal year 2025. That is unchanged from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Provectus Biopha held $251K in cash as of fiscal year 2025; long-term debt is not reported for that period.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
None of these metrics is reported for fiscal year 2025.
Capital Allocation
Provectus Biopha invested $1.9M in research and development in fiscal year 2025. This represents a decrease of 7.5% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
PVCT Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $336K-45.5% | $617K+10.7% | $558K-43.6% | $989K | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| R&D Expenses | N/A | $1.9M-7.5% | $2.1M+17.2% | $1.7M-26.8% | $2.4M-8.4% | $2.6M-7.3% | $2.8M-29.7% | $4.0M-15.7% | $4.7M-42.1% | $8.2M-0.1% | $8.2M-27.8% | $11.4M+95.9% | $5.8M+61.6% | $3.6M-28.2% | $5.0M-43.2% | $8.8M |
| SG&A Expenses | N/A | N/A | $3.1M+81.2% | $1.7M-15.7% | $2.0M-1.8% | $2.1M-4.0% | $2.2M-6.4% | $2.3M-30.5% | $3.3M-35.4% | $5.1M-68.6% | $16.3M+22.8% | $13.3M+20.6% | $11.0M+25.6% | $8.8M+1.2% | $8.7M-27.6% | $12.0M |
| Operating Income | N/A | N/A | -$4.5M-56.2% | -$2.9M+15.4% | -$3.4M+26.6% | -$4.7M | N/A | -$6.3M+21.8% | -$8.1M+39.5% | -$13.3M+45.7% | -$24.5M+0.6% | -$24.7M-95.2% | -$12.6M+3.0% | -$13.0M+9.1% | -$14.3M+33.1% | -$21.4M |
| Interest Expense | N/A | $5K-60.7% | $14K+140.5% | $6K+65.7% | $3K-99.6% | $962K-45.0% | $1.7M+20.1% | $1.5M+50.1% | $970K | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $0 | $0 | $0 | $0 | N/A |
| Net Income | N/A | N/A | $4.8M+53.5% | $3.1M+187.3% | -$3.6M+35.8% | -$5.5M | N/A | -$6.9M+15.1% | -$8.2M+39.7% | -$13.5M+44.7% | -$24.4M+0.3% | -$24.5M-139.2% | -$10.2M+63.0% | -$27.7M-120.4% | -$12.6M+35.3% | -$19.4M |
| EPS (Diluted) | — | -$0.010.0% | -$0.010.0% | -$0.010.0% | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PVCT Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $698K-30.7% | $1.0M-30.5% | $1.4M-28.9% | $2.0M-42.0% | $3.5M+496.3% | $589K-60.1% | $1.5M-25.7% | $2.0M-42.1% | $3.4M-38.8% | $5.6M-72.5% | $20.4M-21.9% | $26.2M+30.9% | $20.0M+222.5% | $6.2M-53.5% | $13.3M |
| Current Assets | $568K-41.9% | $977K-28.4% | $1.4M-28.1% | $1.9M-44.8% | $3.4M+712.4% | $424K-57.5% | $996K-2.0% | $1.0M+6.1% | $958K-47.5% | $1.8M-87.6% | $14.7M-22.9% | $19.1M+21.7% | $15.7M+1184.8% | $1.2M-84.1% | $7.7M |
| Cash & Equivalents | $251K-18.3% | $307K+301.5% | $77K+254.4% | $22K-96.8% | $683K+602.4% | $97K-83.5% | $591K+1058.6% | $51K-51.7% | $106K-90.9% | $1.2M-91.8% | $14.2M-18.5% | $17.4M+10.8% | $15.7M+1184.8% | $1.2M-84.1% | $7.7M |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | $4K-92.9% | $55K-90.8% | $595K | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $7.0M+0.4% | $7.0M-22.9% | $9.0M+9.4% | $8.3M+7.3% | $7.7M-75.0% | $30.8M+20.5% | $25.5M+31.7% | $19.4M+44.2% | $13.5M+528.2% | $2.1M-48.1% | $4.1M+314.7% | $994K-92.6% | $13.4M+638.8% | $1.8M-45.6% | $3.3M |
| Current Liabilities | $6.9M-1.1% | $7.0M-22.6% | $9.0M+10.1% | $8.2M+6.4% | $7.7M-74.9% | $30.7M+916.0% | $3.0M-26.3% | $4.1M+14.0% | $3.6M+68.0% | $2.1M-48.1% | $4.1M+386.3% | $848K+65.3% | $513K+0.3% | $511K+94.7% | $263K |
| Total Equity | -$6.3M-5.7% | -$6.0M+21.5% | -$7.6M-21.9% | -$6.2M-48.7% | -$4.2M+86.1% | -$30.2M-25.5% | -$24.1M-38.2% | -$17.4M-73.8% | -$10.0M-388.8% | $3.5M-78.7% | $16.3M-35.2% | $25.2M+280.0% | $6.6M+50.9% | $4.4M-56.2% | $10.0M |
| Retained Earnings | -$262.9M-2.1% | -$257.4M-1.9% | -$252.7M-1.2% | -$249.6M-1.4% | -$246.0M-2.3% | -$240.5M-2.9% | -$233.8M-3.1% | -$226.9M-3.7% | -$218.7M-6.6% | -$205.2M-13.5% | -$180.8M-15.7% | -$156.3M-7.0% | -$146.1M-23.4% | -$118.4M-11.9% | -$105.8M |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
PVCT Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.4M | -$3.3M-1.3% | -$3.3M-27.7% | -$2.6M+15.4% | -$3.0M-200.2% | -$1.0M | N/A | -$6.2M-18.9% | -$5.2M+49.7% | -$10.3M+52.8% | -$21.9M-26.0% | -$17.4M-25.7% | -$13.8M-40.0% | -$9.9M+12.1% | -$11.3M+34.5% | -$17.2M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $30K | N/A | $6K-91.3% | $71K+961.5% | $7K-58.1% | $16K+158.4% | $6K |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$10.4M | N/A | -$17.4M-25.1% | -$13.9M-40.6% | -$9.9M+12.2% | -$11.3M+34.5% | -$17.2M |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -$30K | N/A | N/A | -$71K-961.5% | -$7K+58.1% | -$16K-158.4% | -$6K |
| Financing Cash Flow | $3.2M | $3.1M+12.3% | $2.7M+25.4% | $2.2M+60.2% | $1.4M-66.0% | $4.0M | N/A | $6.8M+31.1% | $5.2M-44.7% | $9.3M | N/A | N/A | N/A | $24.4M+408.8% | $4.8M-71.5% | $16.8M |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
PVCT Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -734.4% | -520.2% | -346.6% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | 771.6% | 556.2% | -359.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -704.1%-554.0pp | -150.2%-109.5pp | -40.7%+377.2pp | -417.8%-131.8pp | -286.1%-92.1pp | -194.0% |
| Return on Assets | N/A | 473.3%+259.2pp | 214.1%+388.6pp | -174.5%-16.8pp | -157.7% | N/A | -468.7%-58.7pp | -410.1%-16.7pp | -393.4%+42.0pp | -435.4%-315.5pp | -119.9%-80.8pp | -39.1%+99.3pp | -138.4%+64.1pp | -202.6%-57.0pp | -145.6% |
| Current Ratio | 0.08-0.1x | 0.140.0x | 0.15-0.1x | 0.23-0.2x | 0.45+0.4x | 0.01-0.3x | 0.33+0.1x | 0.250.0x | 0.27-0.6x | 0.85-2.7x | 3.57-19.0x | 22.53-8.1x | 30.60+28.2x | 2.39-26.9x | 29.33 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.62+0.4x | 0.25+0.2x | 0.04-2.0x | 2.02+1.6x | 0.41+0.1x | 0.33 |
Not reported in any period shown, so not listed: Gross Margin, FCF Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.
Note: Shareholder equity is negative (-$6.3M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.08), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Where Provectus Biopha Ranks
Frequently Asked Questions
What is Provectus Biopha's annual revenue?
Provectus Biopha (PVCT) reported $336K in total revenue for fiscal year 2025. This represents a -45.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Provectus Biopha's revenue growing?
Provectus Biopha (PVCT) revenue declined by 45.5% year-over-year, from $617K to $336K in fiscal year 2025.
What is Provectus Biopha's operating cash flow?
Provectus Biopha (PVCT) recorded an outflow of $3.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Provectus Biopha's total assets?
Provectus Biopha (PVCT) had $698K in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Provectus Biopha spend on research and development?
Provectus Biopha (PVCT) invested $1.9M in research and development during fiscal year 2025.
What is Provectus Biopha's current ratio?
Provectus Biopha (PVCT) had a current ratio of 0.08 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is Provectus Biopha's cash runway?
Based on fiscal year 2025 data, Provectus Biopha (PVCT) had $251K in cash against an annual operating cash burn of $3.3M. This gives an estimated cash runway of approximately 1 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is Provectus Biopha's debt-to-equity ratio negative or not reported?
Provectus Biopha (PVCT) has negative shareholder equity of -$6.3M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.